Enveric Biosciences, Inc. (Nasdaq: ENVB) said that has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for another patent application involving its EVM201 Series

The soon-to-issue patent, titled "C4-Carboxylic Acid-Substituted Tryptamine Derivatives and Methods of Using," covers composition of matter claims for a novel family of prodrug derivatives of psilocin, distinct from the Notice of Allowance announced 6 days ago. These patents are expected to provide Enveric with a strong intellectual property portfolio for psilocin prodrugs, offering potential benefits such as faster onset, controlled therapeutic effects, and reduced gastrointestinal side effects compared to conventional psilocin prodrugs like psilocybin.

Following this announcement, $ENVB is trading at $6.17, reflecting a significant increase of $3.02 (+95.87%).

In other news, Immutep Limited (Nasdaq: IMMP) has released positive clinical data from the INSIGHT-003, a Phase I trial evaluating eftilagimod alpha ("efti") in 1st line non-small cell lung cancer. According to the company, the data suggests that the combination of Efti with standard-of-care anti-PD-1 therapy and doublet chemotherapy is well tolerated and demonstrates promising initial efficacy signals.

$IMMP is currently trading at $2.55, experiencing a rise of $0.25 (+10.87%).

Furthermore, IDEAYA Biosciences, Inc. (Nasdaq: IDYA) has been initiated with a Buy rating and a price target of $32 at Goldman Sachs.

$IDYA is trading at $22.00, indicating a slight increase of $0.10 (+0.47%).

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer)